OxyContin maker Purdue Pharma said on Saturday that it has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways drugmakers market addictive painkillers.
The drugmaker said it will inform doctors Monday that its sales representatives will no longer visit physicians’ offices to discuss the company’s opioid products. It will now have about 200 sales representatives, Purdue said.
“We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers,” the company, based in Stamford, Conn., said in a statement.
Doctors with questions about opioids will be directed to the company’s medical affairs department. Its sales representatives will focus on Symproic, a drug for treating opioid-induced constipation, as well as other potential non-opioid products, Purdue said.